Cargando…
A Decade of Marketing Authorization Applications of Anticancer Drugs in the European Union: An Analysis of Procedural Timelines
BACKGROUND: Cancer is a serious global health problem and a major cause of death. The European Medicines Agency (EMA) has established several regulatory initiatives to expedite the development and authorization of drugs to ensure timely access of patients. In this study, we analyzed the procedural t...
Autores principales: | Garsen, Marjolein, Steenhof, Maaike, Zwiers, Alex |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238922/ https://www.ncbi.nlm.nih.gov/pubmed/33543409 http://dx.doi.org/10.1007/s43441-021-00260-5 |
Ejemplares similares
-
Healthy Volunteer Studies in the Development of Anticancer Drugs with Genotoxic Findings
por: Omes-Smit, Grace, et al.
Publicado: (2021) -
Decade timeline
Publicado: (2009) -
A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU
por: da Costa Gonçalves, Fabiany, et al.
Publicado: (2022) -
Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union
por: Pellegrini, Graziella, et al.
Publicado: (2017) -
Scrutinizing Pork Price Volatility in the European Union over the Last Decade
por: Utnik-Banaś, Katarzyna, et al.
Publicado: (2022)